Showing results (1761-1770 of 1,882) with videos related to

Sort By:
Pageof 189
American Journal of Perinatology|May 15, 2013
Nonclinical parameters affecting primary cesarean rates in the United StatesShoshana Haberman, Sumit Saraf, Jun Zhang, et al.
Plos One|June 9, 2022
Differential antibody production by symptomatology in SARS-CoV-2 convalescent individualsSharada Saraf, Xianming Zhu, Ruchee Shrestha, et al.
World Journal of Pediatrics : WJP|November 24, 2021
Consensus statement on the epidemiology, diagnosis, prevention, and management of cow's milk protein allergy in the Middle East: a modified Delphi-based studyMoustafa A El-Hodhod, Mortada H F El-Shabrawi, Ahmed AlBadi, et al.
Plos One|December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinomaBert H O'Neil, John M Wallmark, David Lorente, et al.
Virus Evolution|August 7, 2023
Dating reservoir formation in virologically suppressed people living with HIV-1 in Rakai, UgandaEdward Nelson Kankaka, Andrew D Redd, Amjad Khan, et al.
American Journal of Clinical Oncology|February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 StudyRoger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 29, 2022
Lessons Learned From Five Years of Newborn Screening for Severe Combined Immunodeficiency in IsraelAtar Lev, Idan Sharir, Amos J Simon, et al.
Genome Biology and Evolution|May 19, 2016
Opsin Repertoire and Expression Patterns in Horseshoe Crabs: Evidence from the Genome of Limulus polyphemus (Arthropoda: Chelicerata)Barbara-Anne Battelle, Joseph F Ryan, Karen E Kempler, et al.
Nature Immunology|August 14, 2019
The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradationMaria Guillamot, Dahmane Ouazia, Igor Dolgalev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerHope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.
Pageof 189